Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Tye

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 1, 2013
Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in ratsSteven V Fox, Anthony L Gotter, Spencer J Tye, et al.
Journal of Medicinal Chemistry|April 14, 2006
A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxietyRichard T Lewis, Wesley P Blackaby, Timothy Blackburn, et al.
BMC Neuroscience|August 29, 2013
The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy thresholdAnthony L Gotter, Christopher J Winrow, Joseph Brunner, et al.
Bioorganic & Medicinal Chemistry Letters|January 3, 2006
Imidazo[1,2-b][1,2,4]triazines as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxietyAndrew S R Jennings, Richard T Lewis, Michael G N Russell, et al.
Journal of Affective Disorders|May 29, 2018
Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disordersAhmed T Ahmed, Mark A Frye, A John Rush, et al.
Science Translational Medicine|April 5, 2013
Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognitionJason M Uslaner, Spencer J Tye, Donnie M Eddins, et al.
Journal of Affective Disorders|December 24, 2023
Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depressionSagar V Parikh, Jennifer L Vande Voort, Anastasia K Yocum, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 18, 2005
Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepinesRebecca Dias, Wayne F A Sheppard, Rosa L Fradley, et al.
Journal of Medicinal Chemistry|February 17, 2006
Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxietyMichael G N Russell, Robert W Carling, Leslie J Street, et al.
Translational Psychiatry|February 13, 2024
Pharmacogenomic overlap between antidepressant treatment response in major depression & antidepressant associated treatment emergent mania in bipolar disorderNicolas A Nuñez, Brandon J Coombes, Lindsay Melhuish Beaupre, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 1, 2013
Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in ratsSteven V Fox, Anthony L Gotter, Spencer J Tye, et al.
Journal of Medicinal Chemistry|April 14, 2006
A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxietyRichard T Lewis, Wesley P Blackaby, Timothy Blackburn, et al.
BMC Neuroscience|August 29, 2013
The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy thresholdAnthony L Gotter, Christopher J Winrow, Joseph Brunner, et al.
Bioorganic & Medicinal Chemistry Letters|January 3, 2006
Imidazo[1,2-b][1,2,4]triazines as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxietyAndrew S R Jennings, Richard T Lewis, Michael G N Russell, et al.
Journal of Affective Disorders|May 29, 2018
Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disordersAhmed T Ahmed, Mark A Frye, A John Rush, et al.
Science Translational Medicine|April 5, 2013
Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognitionJason M Uslaner, Spencer J Tye, Donnie M Eddins, et al.
Journal of Affective Disorders|December 24, 2023
Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depressionSagar V Parikh, Jennifer L Vande Voort, Anastasia K Yocum, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 18, 2005
Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepinesRebecca Dias, Wayne F A Sheppard, Rosa L Fradley, et al.
Journal of Medicinal Chemistry|February 17, 2006
Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxietyMichael G N Russell, Robert W Carling, Leslie J Street, et al.
Translational Psychiatry|February 13, 2024
Pharmacogenomic overlap between antidepressant treatment response in major depression & antidepressant associated treatment emergent mania in bipolar disorderNicolas A Nuñez, Brandon J Coombes, Lindsay Melhuish Beaupre, et al.
Pageof 15